Locations:
Search IconSearch
April 4, 2018/Neurosciences

PACNS or RCVS? Differences in Clinical Presentation

How to tell the difference and why it matters

16-RHE-871-Calabrese-Hero-Image-650x450pxl

By Rula Hajj-Ali, MD, and Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Primary angiitis of the central nervous system (PACNS) is a devastating disease in which exclusive inflammation and destruction of vessels in the CNS cause progressive, debilitating neurological deficits. Prognosis improves greatly with proper treatment, but with nonspecific tests and many confounding mimics, diagnosis can be tricky.

One of PACNS’s closest mimics is reversible cerebral vasoconstriction syndrome (RCVS). The distinguishing characteristic of this group is the “thunderclap” headache — sudden, severe and with or without neurological deficits. Originally, rheumatologists treated RCVS as benign angiopathy of the CNS. In 2007, Calabrese et al set forth RCVS as a concept encompassing several syndromes with unifying clinical, laboratory and radiologic features. The clinical features and diagnostic criteria described in that paper have been considered the standard since its publication.

Distinguishing between RCVS and PACNS is critical because the treatment protocol is so vastly different. Misdiagnosing PACNS as RCVS can deprive a patient of medications that prolong survival and improve outcomes. These conditions are close mimics, but the astute clinician has several tools in her armamentarium to distinguish between them. We offer a brief overview of differences in clinical presentation below. Future posts will discuss differences in test results and management.

Clinical presentation

Patients with PACNS are more commonly male and trend older with a mean age of 50 years at onset, while patients with RCVS are more likely to be female and a bit younger. Patients with both conditions almost always present with headaches, but the differences in onset and type are important to distinguish between the mimics. Patients with PACNS experience subacute onset of headaches with focal and nonfocal deficits; a patient with sudden-onset, severe, “thunderclap” headaches should be considered for RCVS whether or not neurological deficits are present. RCVS is monophasic, but patients with PACNS will experience these symptoms chronically.

Advertisement

When patients present with these symptoms, diagnostic tests can help eliminate the mimics and narrow towards a precise diagnosis.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Advertisement

Related Articles

middle-aged woman with surgical mask looking out a window
Registry Studies Reassure on Impact of COVID-19 in People With MS

No effect on symptom severity or disability, and low prevalence of long COVID

network of nerves on the side of the face
January 14, 2025/Neurosciences/Brain Tumor
Preemptive Facial Nerve Rewiring in the Management of Facial Nerve Tumor: A Case Study

Novel approach begins reinnervation before tumor resection, preserving a young woman’s smile

Medical illustration of brain
January 6, 2025/Neurosciences/Research
Department of Defense Awards $3.4 Million to Advance a Tool for Assessing Return-to-Duty Readiness After Brain Injury

Cleveland Clinic researchers collaborate with Microsoft to create a product ready for the field

smartwatch being strapped to a woman's wrist
December 20, 2024/Neurosciences/Brain Tumor
Can Smartwatch Data Predict Progression and Detect Complications in Patients With Glioblastoma?

Researchers use AI tools to compare clinical events with continuous patient monitoring

Dr. Charles Bernick against a decorative backdrop
December 13, 2024/Neurosciences/Podcast
Considerations Around the Use of Anti-Amyloid Agents for Alzheimer’s Disease (Podcast)

Guidance on patient selection, safety surveillance, choosing among agents and more

macrophages and microglia in glioblastoma tumors
December 3, 2024/Neurosciences/Brain Tumor
Dual Targeting of Macrophages and Microglia Shows Promise in Preclinical Glioblastoma Models

Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression

portrait of dr. demitre serletis against decorative background
December 2, 2024/Neurosciences/Podcast
SEEG in Epilepsy Surgery Evaluation: Current and Future Roles (Podcast)

Insights on how stereoelectroencephalography is continuing to improve seizure localization

brain map showing planned electrode placement
November 25, 2024/Neurosciences/Epilepsy
What We’ve Learned From Our First 1,000 Cases of SEEG Evaluation

Progress in stereoelectroencephalography for epilepsy surgery evaluation since Cleveland Clinic performed the first U.S. case in 2009

Ad